MDT Medtronic Plc

Medtronic Launches Efficioâ„¢ Software to Help Clinicians Efficiently Manage Targeted Drug Delivery Therapy with SynchroMedâ„¢ II

Medtronic Launches Efficio™ Software to Help Clinicians Efficiently Manage Targeted Drug Delivery Therapy with SynchroMed™ II

 Efficio Software Provides Enhanced, Secure Access to Patient Data and Delivers

Actionable Insights in a Secure Cloud Environment

DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (NYSE:MDT) today announced the launch of Efficio™, a cloud-based data management software for use with the SynchroMed™ II intrathecal drug delivery system, that will allow clinicians to more efficiently manage their targeted drug delivery pump practices to treat patients with chronic pain, cancer pain and severe spasticity.

Efficio management software allows clinicians to manage patients’ pumps with greater efficiency and ease by consolidating, organizing and providing visual summaries of patient data from the clinician programmer in a secure cloud environment accessible at anytime, anywhere. Efficio connects individual patient measures and dosing trends, which can help clinicians unlock powerful therapy management insights. Additional benefits include the ability to proactively schedule patient appointments, facilitate prescription drug order tracking for pump refills, and printing reports on-demand. With Efficio, clinicians can manage patient data without the use of spreadsheets and easily export data into their electronic medical records systems as appropriate.

“For years, clinicians have been managing pump patients on their own with internal spreadsheets and other manual processes,” said Chris Beuer, M.D., director of pain management at Christian Hospital in St. Louis, Mo., who was involved with the pilot program. “Now, with the click of a button, I can understand the dosing history of an individual patient or produce end-of-day reports within minutes. Efficio also helps me manage pump refill dates, pump replacements, and monitor trends in dosing and patient function. It provides tremendous value to my practice, allowing me to focus more time caring for my patients.”

“Efficio marks another step in our journey to simplify targeted drug delivery therapy,” said Charlie Covert, vice president and general manager of the Targeted Drug Delivery business, which is part of the Restorative Therapies Group at Medtronic. “We believe providing innovative solutions that simplify management of the therapy will enable clinicians to reduce pain or severe spasticity symptoms for even more patients with this proven therapy.”

Efficio software supports HIPAA compliance and is designed to safeguard protected health information. Data is protected using encryption and authentication. Access restrictions and login time limits are also in place to help protect data. To learn more about Efficio software, please visit .

About SynchroMed™ II Intrathecal Drug Delivery System

The SynchroMed II intrathecal drug delivery system offers a safe, proven, and effective way to manage chronic pain, cancer pain and severe spasticity for appropriate patients. SynchroMed II provides effective pain relief at a fraction of the oral dose with fewer side effects and has been shown to reduce or eliminate the use of oral opioids.1-4 A programmable pump and catheter are implanted under the skin and deliver prescribed amounts of medication directly into the intrathecal space near pain receptors in the spine instead of the circulatory system. The implanted pump stores and dispenses medication inside the body, reducing the opportunity for diversion of the drug, and misuse by individuals who are not prescribed the opioids.

About Medtronic Pain Therapies

Medtronic has more than a 40-year history of developing innovative medical devices that have been shown to alleviate pain in different disease states and has a broad portfolio of device-delivered therapies that are alternatives or adjuncts to oral opioids.3 Medtronic strives to be at the forefront of medical device innovation and to develop high-quality pain therapies that reduce pain and improve quality of life. While Medtronic pain therapies do not treat opioid addiction, the company is committed to leveraging its capabilities and product portfolio in partnership with stakeholders - patients, providers, payers, regulators, elected officials, patient advocacy groups and employers - to address the unmet needs of pain patients and to support efforts to prevent opioid misuse due to chronic intractable pain.

About Medtronic

Medtronic plc (), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

References

  1. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002;20(19):4040-4049.
  2. Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13(10): 1304-1313.
  3. Grider JS, Etscheidt MA, Harned ME, et al. Trialing and maintenance dosing using a low-dose intrathecal opioid method for chronic nonmalignant pain: a prospective 36-month study. Neuromodulation : journal of the International Neuromodulation Society. 2016;19(2):206-219.
  4. Hatheway JA, Caraway D, David G, et al. Oral opioid elimination after implantation of an intrathecal drug delivery system significantly reduced health-care expenditures. Neuromodulation : journal of the International Neuromodulation Society. 2015;18(3):207-213.



Michelle Claypool

Public Relations

Ryan Weispfenning

Investor Relations

EN
23/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Prior Breakout Level DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. While the dust has yet to settle, the good news is that the selloff has been largely contained to these AI-linked stocks. The rest of the market did not seem to care; the equal-weighted S&P 500 was roughly flat yesterday. Additionally, market dynamics remain healthy, with Treasury yields, the U.S. dollar (DXY), and WTI crude oil continuing to move lower, and...

Medtronic, Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong product diversification, offset by its large payouts to shareholders.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch